IL6 and Hypertension: While our findings do not support the use of interleukin-6 inhibitors in adults with preclinical hypertension, they highlight that inflammation is evident early in the course of the disease and suggest the potential value of preventive strategies targeting inflammation to reduce cardiovascular risk in this population.